1. Editorial Slides - VP Watch, September 5th
, 2001, Volume 1, Issue 25
Is coated stent THE answer?
2. In-Stent Restenosis = Neointimal Hyperplasia
The long-term clinical efficacy of intracoronary stenting is
limited by restenosis which, occurs in 15-30 % of patients. In-
stent restenosis is due solely to neointimal hyperplasia.
Shape and chemical biocompatibility of stent, and the extent of
inflammatory response to stenting are among major factors
predicting restenosis. Intravascular radiation has shown
significant benefit however the cost, repated interventions,
radiation safety, short and long term adverse effect all remain
unresolved issues.
Experimental data suggest that in-situ immunosuppressant and
inhibitors of cell cycle progression may be an effective strategy
to prevent restenosis.
3. Effects of drug-coated stents on arterial repair
Suzuki et al., Circulation. 2001;104:1188
Endothelium
SM
C
Fibrin
0
1/2
1
1 1/2
2
2 1/2
3
Repairscore
Control
Dexametasone
Sirolimus
SRL+DEX
From VP Watch this week:
High-power
photomicrographs
of bare metal (B) and
SRL-coated (C) stents
4. As highlighted in VP Watch this week, Suzuki, Carter, et al.
determined that stents coated with a nonerodable polymer
matrix containing 185 µg SRL compared with a bare metal
stent reduces restenosis by 50% through inhibiting cellular
proliferation. The dose-response effects for this SRL-eluting
stent are incompletely characterized but, they indicated a dose-
dependent reduction in intimal hyperplasia with 60 µg to 200
µg SRL–coated stents in the rabbit model.
Circulation 2001;104:1188
Also Suzuki et al. also showed that stent-based delivery of
dexamethasone (DEX) alone is insufficient to inhibit neointimal
formation. They did not observed any synergism in combination
of dexamethasonwith SRL.
Circulation 2001;104:1188
5. It was shown years go that intraperitoneal administration of SRL, a potent
immunosuppressive agent, resulted in a dose-dependent inhibition of arterial
intimal thickening caused by either chronic alloimmune or mechanical injury
in a rat model. (Gregory CR, Huie P, Billingham ME, et al., Transplantation.
1993; 55: 1409–1418)
Other studies about the effect of Sirolimus on restenosis:
Other studies also show that SRL inhibits the proliferation of vascular SMC
in human and rat in vitro by blocking the G1
/S transition. (Poon M et al., J
Clin Invest. 1996; 98: 2277–2283 and Marx SO et al., Circ Res. 1995; 76: 412–
417)
Study of Gallo et al. indicates that systemic SRL therapy significantly
reduces the proliferative response after coronary angioplasty in the porcine
model. (Circulation. 1999; 99: 2164–2170)
6. Latest on Sirulimon restenosis clinical trial:
The RAVEL study this week
reported “zero” restenosis at 210
days.
Congress of European Society of Cardiology
Stockholm Sep 1-5th
7. Conclusion:
Stent-based delivery of Sirolimus via a nonerodable
polymer matrix is feasible and effectively reduces restenosis.
Adding dexamethasone did not offer additional benefit.
If RAVEL holds true for 5 years, the immunosuppressant
RAPAMUNE® (Sirolimus) coated stents becomes the standard
therapy for coronary revascularization.
8. Questions:
Feel free to send your response to:
Discussion-Group@VulnerablePlaque.org
Knowing atherosclerosis as a diffuse disease, do you think that
stenting vulnerable plaques with coated stents can be the
treatment of choice besides statins?
If the coated stent reduces restenosis by 90%, will you stent
every vulnerable plaque? What if you find 3, 4, 5 or more
vulnerable plaques in one patient?
